- Home
- CMMB vs RDHL Comparison
CMMB vs RDHL Comparison
Compare CMMB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- RDHL
- Stock Information
- Founded
- CMMB 2004
- RDHL 2009
- Country
- CMMB Israel
- RDHL Israel
- Employees
- CMMB N/A
- RDHL N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- RDHL Health Care
- Exchange
- CMMB Nasdaq
- RDHL Nasdaq
- Market Cap
- CMMB N/A
- RDHL 8.6M
- IPO Year
- CMMB N/A
- RDHL N/A
- Fundamental
- Price
- CMMB $1.68
- RDHL $6.50
- Analyst Decision
- CMMB Strong Buy
- RDHL
- Analyst Count
- CMMB 3
- RDHL 0
- Target Price
- CMMB $7.33
- RDHL N/A
- AVG Volume (30 Days)
- CMMB 87.3K
- RDHL 21.3K
- Earning Date
- CMMB 11-14-2024
- RDHL 12-27-2024
- Dividend Yield
- CMMB N/A
- RDHL N/A
- EPS Growth
- CMMB N/A
- RDHL N/A
- EPS
- CMMB N/A
- RDHL N/A
- Revenue
- CMMB N/A
- RDHL $3,707,000.00
- Revenue This Year
- CMMB N/A
- RDHL $224.90
- Revenue Next Year
- CMMB N/A
- RDHL $82.69
- P/E Ratio
- CMMB N/A
- RDHL N/A
- Revenue Growth
- CMMB N/A
- RDHL N/A
- 52 Week Low
- CMMB $0.45
- RDHL $6.00
- 52 Week High
- CMMB $2.55
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- CMMB 52.44
- RDHL 38.21
- Support Level
- CMMB $1.53
- RDHL $6.00
- Resistance Level
- CMMB $1.71
- RDHL $7.30
- Average True Range (ATR)
- CMMB 0.11
- RDHL 0.51
- MACD
- CMMB -0.01
- RDHL -0.09
- Stochastic Oscillator
- CMMB 39.47
- RDHL 21.10
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.